We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00573326
Recruitment Status : Unknown
Verified September 2009 by Azienda Ospedaliera Universitaria Policlinico.
Recruitment status was:  Recruiting
First Posted : December 14, 2007
Last Update Posted : September 3, 2009
Università Politecnica delle Marche
Information provided by:
Azienda Ospedaliera Universitaria Policlinico

Brief Summary:
The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Drug: Imatinib Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study
Study Start Date : February 2009
Estimated Primary Completion Date : June 2010
Estimated Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma

Arm Intervention/treatment
Experimental: 1
Imatinib 200 mg p.o. once a day for 6 months
Drug: Imatinib
200 mg p.o. once a day for 6 months

Primary Outcome Measures :
  1. Improvement of the pulmonary interstitial disease, evaluated by spirometry and DLCO, lung HRCTscan, emogasanalysis. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Cutaneous Involvement, evaluated by the modified Rodnan skin score; quality of life and patient physical and emotional well being, evaluated by SF-36 score and HAQ [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • SSc with active pulmonary involvement refractory to conventional immunosuppressive regimen
  • Presence of active interstitial alveolitis (presence of grade 2 exertional dyspnea according to Mahler Dyspnea Index AND worsening of lung function tests PLUS interstitial alveolitis assessed by HRCTscan, ground-glass pattern involving at least two lung segments OR dyspnea (as defined above)PLUS Interstitial alveolitis assessed by HRCTscan (AS DEFINED ABOVE) AND neutrophilic or eosinophilic alveolitis detected through broncoalveolar lavage
  • Resistance to conventional immunosuppressive treatment (worsening or lack of improvement of lung function tests after cyclophosphamide therapy, conducted for at least three months, with a cumulative dosage > or = 6 g
  • Age 18-80 years
  • Ability ti give an informed consent
  • Use of an acceptable method of birth control; pregnancy will be ruled out before study beginning

Exclusion Criteria:

  • Connective tissue diseases other than SSc
  • Smoking Habit
  • Pregnancy or lactation
  • HBV or HCV infection
  • Severe anaemia (Hb< or = 8g/dl)
  • Hepatic disease (ALT or ALP>1.5 fold above normal levels)
  • Moderate or severe renal failure (creatinine clearance<59ml/min)
  • Severe heart failure, with ejection fraction < or = 35% measured by echocardiography
  • thyroid disease with clinical evidence of hyperthyroidism treated with substitutive therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00573326

Layout table for location contacts
Contact: Paolo Fraticelli, Dr +390715964256 p.fraticelli@ospedaliriuniti.marche.it
Contact: Armando Gabrielli, Professor +390712206104 a.gabrielli@univpm.it

Layout table for location information
Università Politecnica delle Marche Recruiting
Ancona, Italy, 60020
Contact: Paolo Fraticelli, Dr    +390715964256    p.fraticelli@ospedaliriuniti.marche.it   
Sponsors and Collaborators
Azienda Ospedaliera Universitaria Policlinico
Università Politecnica delle Marche
Layout table for investigator information
Study Chair: Armando Gabrielli, MD Università Politecnica delle Marche
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Paolo Fraticelli/MD, Università Politecnica delle Marche
ClinicalTrials.gov Identifier: NCT00573326    
Other Study ID Numbers: FARM 69J AJ9
EudraCT code:2007-005322-68
First Posted: December 14, 2007    Key Record Dates
Last Update Posted: September 3, 2009
Last Verified: September 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Connective Tissue Diseases
Skin Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action